GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » IM Cannabis Corp (NAS:IMCC) » Definitions » Capex-to-Revenue

IMCC (IM Cannabis) Capex-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is IM Cannabis Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

IM Cannabis's Capital Expenditure for the three months ended in Dec. 2024 was $-0.02 Mil. Its Revenue for the three months ended in Dec. 2024 was $9.36 Mil.

Hence, IM Cannabis's Capex-to-Revenue for the three months ended in Dec. 2024 was 0.00.


IM Cannabis Capex-to-Revenue Historical Data

The historical data trend for IM Cannabis's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IM Cannabis Capex-to-Revenue Chart

IM Cannabis Annual Data
Trend Apr14 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.14 0.03 0.01 -

IM Cannabis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 -

Competitive Comparison of IM Cannabis's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, IM Cannabis's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IM Cannabis's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, IM Cannabis's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where IM Cannabis's Capex-to-Revenue falls into.


;
;

IM Cannabis Capex-to-Revenue Calculation

IM Cannabis's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.109) / 37.924
=0.00

IM Cannabis's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.021) / 9.36
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IM Cannabis  (NAS:IMCC) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


IM Cannabis Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of IM Cannabis's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


IM Cannabis Business Description

Traded in Other Exchanges
Address
Central District, Kibbutz Glil Yam, ISR, 4690500
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.